Clinical Trials Browser

NETWORK × Interventional × Gefitinib × Clear all

NCT00352079 2023-08-04

BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer

Phase 3 Terminated

Urinary Bladder Neoplasms

NCT00025116 2020-04-06

ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 2 Completed

Prostatic Neoplasms

NCT00467077 2017-03-17

Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer

Phase 2 Terminated

21 enrolled 8 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00066378 2013-10-24

Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT00014144 2012-10-08

S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract

Phase 2 Completed

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00052754 2012-09-24

Gefitinib in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma

Phase 2 Completed

Sarcoma, Sarcoma, Synovial

NCT00066339 2012-07-18

Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor Therapy

Phase 2 Completed

Breast Neoplasms

NCT00091156 2012-07-16

Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 3 Terminated

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00103051 2012-07-16

Gemcitabine, Cisplatin, and Gefitinib in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00052169 2007-12-18

Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer

Phase 2 Completed

Breast Neoplasms